



## Therapeutics for Ferroptosis in CNS Disease

Guest Editor:

### Prof. Dr. Alberto Lazarowski

Institute for Research in  
Physiopathology and Clinical  
Biochemistry (INFIBIOC), Clinical  
Biochemistry Department,  
School of Pharmacy and  
Biochemistry (FFyB), University of  
Buenos Aires, Buenos Aires,  
Argentina

Deadline for manuscript  
submissions:

**closed (20 June 2024)**

### Message from the Guest Editor

Iron (Fe) is a vital element in oxygen transport, enzyme activity, and oxide-reduction reactions for almost all organisms. However, iron is responsible for a recently described programmed cell death mechanism. This process is known as ferroptosis, where antioxidant defenses such as glutathione peroxidase 4 (GPX4) are inhibited or overwhelmed. For proper intracellular use, iron must cross biological membranes, which requires conversion from its oxidized to reduced state and vice versa, depending on the metabolic step involved. The complex molecular mechanisms involved in ferroptosis can be activated in all cell types, including those of the CNS, developing degenerative (NDG) processes also known as neurodegeneration. The progressive loss of neural functions and neuronal death with iron accumulation is closely associated with intellectual and/or motor impairment. In this Special Issue of *Pharmaceuticals*, we intend to update the most relevant information on the potential therapeutic action of ferroptosis in the CNS, with a focus on its implication in different types of neurological pathologies and its most representative biomarkers.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

## Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

*Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

## Contact Us

*Pharmaceuticals* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/pharmaceuticals](http://mdpi.com/journal/pharmaceuticals)  
[pharmaceuticals@mdpi.com](mailto:pharmaceuticals@mdpi.com)  
[X@Pharmaceut\\_MDPI](https://twitter.com/Pharmaceut_MDPI)